ESR1 and neoplasm: VT02956 treatment had marginally effect on the growth of LATS1/2 dKO nor YAP/TAZ dKO cells (Fig. 6c), demonstrating that VT02956 targets the LATS-YAP/TAZ-ERα axis to inhibit ER+ tumours cell growth.